Update on cardiotoxicity of anti-cancer treatments, Eur J Clin Invest, vol.46, pp.264-84, 2016. ,
Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment, Curr Cardiol Rev, vol.7, pp.214-234, 2011. ,
Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies, Cancer Treat Rev, vol.59, pp.123-154, 2017. ,
Shared risk factors in cardiovascular disease and cancer, Circulation, vol.133, pp.1104-1118, 2016. ,
Curie Institute Breast Cancer Group. Overweight, obesity and breast cancer prognosis: optimal body size indicator cut-points, Breast Cancer Res Treat, vol.115, p.18546073, 2009. ,
Is obesity an independent prognosis factor in woman breast cancer?, Breast Cancer Res Treat, vol.111, p.17939036, 2008. ,
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms, Nat Rev Cancer, vol.4, pp.579-91, 2004. ,
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies, Lancet, vol.371, pp.569-78, 2008. ,
Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis, J Clin Oncol, vol.34, pp.3157-65, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01413012
High fat diet-fed obese rats are highly sensitive to doxorubicin-induced cardiotoxicity, Toxicol Appl Pharmacol, vol.231, pp.413-435, 2008. ,
Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity, Cancer Chemother Pharmacol, vol.77, p.26914236, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01431557
UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer ,
, , vol.4, p.562, 2019.
ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), Eur Heart J, vol.37, pp.2768-801, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01788726
, Physical status: the use and interpretation of anthropometry, Report of a WHO Expert Committee. World Health Organ Tech Rep Ser, vol.14, pp.1-452, 1995.
Prevention and monitoring of cardiac dysfunction in survivors of adult cancers, J Clin Oncol, vol.35, pp.893-911, 2017. ,
Anthracycline chemotherapy and cardiotoxicity, Cardiovasc Drugs Ther, vol.31, p.28185035, 2017. ,
Cardiac complications of chemotherapy: role of biomarkers, Curr Treat Options Cardiovasc Med, vol.16, p.24771223, 2014. ,
Noninvasive imaging of cardiovascular injury related to the treatment of cancer, JACC Cardiovasc Imaging, vol.7, pp.824-862, 2014. ,
Cardiovascular risk in cancer survivors, Curr Treat Options Cardiovasc Med, vol.20, p.47, 2018. ,
Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk, Circ Genom Precis Med, vol.11, 2018. ,
Body mass index and vigorous physical activity and the risk of heart failure among men, Circulation, vol.119, pp.44-52, 2009. ,
The epidemiologic association between obesity and heart failure, Am Coll Cardiol Ext Learn, vol.49, pp.4-6, 2017. ,
Association of obesity with severity of heart failure exacerbation: a population-based study, J Am Heart Assoc, vol.7, 2018. ,
Lisinopril or Coreg CR in reducing cardiotoxicity in women with breast cancer receiving trastuzumab: a rationale and design of a randomized clinical trial, Am Heart J, vol.188, pp.87-92, 2017. ,
Obesity and cardiovascular disease: revisiting an old relationship, Metabolism, vol.92, pp.98-107, 2019. ,
Adipokines in inflammation and metabolic disease, Nat Rev Immunol, vol.11, pp.85-97, 2011. ,